STOCK TITAN

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced the granting of stock options for 6,100 shares and 4,200 restricted stock units (RSUs) to two new employees as of November 30, 2022. The stock options have an exercise price of $5.29 per share, equivalent to Karyopharm's closing stock price on the grant date. Both stock options and RSUs will vest over four years, with specific conditions for early exercise tied to employment termination scenarios. These grants are in accordance with Nasdaq Listing Rule 5635(c)(4), aimed at facilitating recruitment.

Positive
  • Granting of stock options and RSUs indicates a strategy to attract talent.
  • The exercise price is aligned with the current market, potentially encouraging employee investment.
Negative
  • None.

NEWTON, Mass., Dec. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted stock options to purchase an aggregate of 6,100 shares of Karyopharm's common stock and an aggregate of 4,200 restricted stock units (RSUs) to two newly-hired employees. These equity awards were granted as of November 30, 2022 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Each of the stock options has an exercise price of $5.29 per share, the closing price of Karyopharm's common stock on November 30, 2022. Each stock option will vest over four years, with 25% of the total number of shares underlying the stock option vesting on the one-year anniversary of the applicable employee's employment commencement date and 1/48th of the total number of shares vesting monthly thereafter. Each RSU award will vest over four years, with 25% percent of the shares underlying the RSU award vesting on each of the four consecutive anniversaries of the applicable employee's employment commencement date. The vesting of each inducement award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. In addition, each stock option and RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the applicable stock option or RSU agreement).

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China, Singapore, Canada, Israel, South Korea and Australia. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301690987.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What stock options were granted by Karyopharm Therapeutics on December 1, 2022?

Karyopharm Therapeutics granted stock options to purchase 6,100 shares and 4,200 restricted stock units (RSUs) to two new employees.

What is the exercise price for Karyopharm's stock options granted in December 2022?

The exercise price for the stock options is $5.29 per share.

How long will the stock options and RSUs vest for the new employees at Karyopharm?

Both the stock options and RSUs will vest over a period of four years.

What is the purpose of Karyopharm's stock options and RSUs granted on November 30, 2022?

The equity awards were granted as inducements for the new employees, in accordance with Nasdaq Listing Rule 5635(c)(4).

Can Karyopharm employees exercise their stock options early?

Yes, the stock options can be exercised in full if employment is terminated for good reason or without cause within the first year following a change in control event.

Karyopharm Therapeutics Inc.

NASDAQ:KPTI

KPTI Rankings

KPTI Latest News

KPTI Stock Data

82.52M
117.36M
6.15%
50%
15.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEWTON